Bioluminescence imaging (BLI) using luciferase-expressing cancer cells is a widely adopted method for non-invasive, real-time monitoring of tumor growth, metastasis, and therapeutic responses in vivo. Here, we summarize key considerations for effective implementation of BLI, including luciferin administration and data quantification. We also address common technical challenges and provide practical troubleshooting strategies to support the use of BLI in preclinical tumor models.
Lee et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: